FAQ/Help |
Calendar |
Search |
Today's Posts |
04-01-2013, 02:09 PM | #1 | |||
|
||||
Member
|
Inhaled dopamine agonist clinical trial results.
http://www.ncbi.nlm.nih.gov/pubmed/23527823 Abstract BACKGROUND: 'Off' periods increase as Parkinson's disease (PD) progresses and the benefits of standard therapy wane. Subcutaneous apomorphine rescues 'off' periods, but patient self-injection and adverse cutaneous effects are sometimes problematic. METHODS: We assessed safety, tolerability and efficacy of inhaled dry powder apomorphine (VR040) in a double-blind clinic-based Phase II study. Of 48 patients recruited at nine sites, 47 were randomized 2:1 inhaled apomorphine/placebo. Respirable doses (drug predicted to reach the lung), ascending through 1.5, 2.3, 3.0 and 4.0 mg until efficacy was achieved, were administered to patients in a practically defined 'off' state. The primary endpoint was the response in unified PD rating scale Part 3 (UPDRS 3), at the highest dose received by the patient. Secondary endpoints included time to 'on', the proportion of patients converting from 'off' to 'on', and duration of 'on'. RESULTS: In the 47 intent-to-treat patients with PD, mean age 60.6 years, the mean UPDRS 3 improvement was significantly greater for VR040 at 26.8 points (standard deviation 12.0), vs 14.9 (16.3) for placebo (treatment difference 11.6, 95% confidence interval 2.3-20.9, P = 0.016). Rapid apomorphine absorption (2-7 min) translated to rapid (mean 10 min) reversal from the 'off' state. Adverse effects did not differ between VR040 and placebo; no patient discontinued due to an adverse event; one serious adverse event (constipation) in the VR040 group was considered unrelated to trial medication. CONCLUSIONS: Inhaled apomorphine shows significant promise as a replacement for intermittent subcutaneous injections; further studies are appropriate to optimize efficacy and tolerability.
__________________
Sim00 Born in 1969, diagnosed PD in 2007, first symptoms 2004. DBS in July 2016. |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Titan ... pre-clinical results of continuous delivery of dopamine | Parkinson's Disease | |||
Simpler Language, More Access to Results Sought for Clinical-Trial Volunteers | Parkinson's Disease | |||
new dopamine agonist | Parkinson's Disease | |||
Amantadine for bipolar depression? It is a dopamine agonist. | Bipolar Disorder | |||
GDNF clinical trial results | Parkinson's Disease |